refine search
Authors
Locations
Journals
Publication Dates
Find concepts in Knowledge Base
Explore current query
documentsstatisticstop authorclipboard
9 documents found
1: Title: A previously identified missense mutation in STYXL1 is likely benign.
Authors: Hengel, Holger, et.al. .
Journal: European journal of medical genetics (Eur J Med Genet), 2018 .
Snippet: Based on a homozygous missense variant p.Pro311Ala found in three siblings of a consanguineous family, mutations in the STYXL1 gene were suggested to cause moderate intellectual disability, epilepsy and complex behavioural abnormalities.
Affiliation: Department of Neurology and Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany; German Center of Neurodegenerative Diseases (DZNE), Tübingen, Germany. Department of Neurology and Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany. Caritas Baby Hospital, Bethlehem, Palestine. Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany. Department of Neurology and Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany; German Center of Neurodegenerative Diseases (DZNE), Tübingen, Germany. Electronic address: ludger.schoels@uni-tuebingen.de. .
Related Products: order online
2: Title: Modifier locus mapping of a transgenic F2 mouse population identifies CCDC115 as a novel aggressive prostate cancer modifier gene in humans.
Authors: Winter, Jean M, et.al. .
Journal: BMC genomics, Vol. 19 (1): 450, 2018 .
Snippet: We identified four genes (CCDC115, DNAJC10, RNF149, and STYXL1), which encompassed all of the following characteristics: 1) one or more germline variants associated with aggressive PC traits; 2) differential mRNA levels associated with aggressive PC traits; and 3) differential mRNA expression between normal and tumor tissue.
Affiliation: Metastasis Genetics Section, Genetics and Molecular Biology Branch, National Human Genome Research Institute, NIH, Bethesda, MD, 20892, USA. Present address: Dame Roma Mitchell Cancer Research Laboratories, Adelaide Health and Medical Sciences, The University of Adelaide, Adelaide, South Australia, 5000, Australia. Computational and Statistical Genomics Branch, National Human Genome Research Institute, NIH, Bethesda, MD, 20892, USA. Center for Biomedical Informatics and Information Technology, National Cancer Institute, NIH, Rockville, MD, 20892, USA. Metastasis Genetics Section, Genetics and Molecular Biology Branch, National Human Genome Research Institute, NIH, Bethesda, MD, 20892, USA. nigel.crawford@sanofi.com. , Present address: Sanofi, 55 Corporate Dr., Bridgewater, NJ, 08897, USA. nigel.crawford@sanofi.com. .
Related Products: order online
3: Title: Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection.
Journal: Gynecologic oncology (Gynecol Oncol), 2017 .
Snippet: A panel of 11 AAbs (ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3) provided 45% sensitivity at 98% specificity for serous ovarian cancer, when at least 2 AAbs were above a threshold of 95% specificity.
Affiliation: Division of Cancer Epidemiology, German Cancer Research Center (DFKZ), Heidelberg, Germany. Division of Cancer Epidemiology, German Cancer Research Center (DFKZ), Heidelberg, Germany. Electronic address: r.kaaks@dkfz.de. .
Related Products: order online
4: Title: Autoantibody biomarkers for the detection of serous ovarian cancer.
Authors: Katchman, Benjamin A, et.al. .
Journal: Gynecologic oncology (Gynecol Oncol), Vol. 146 (1): 129-136, 2017 .
Snippet: RESULTS: We identified 11-TAAbs (ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3) that distinguished high-grade serous ovarian cancer cases from healthy controls with a combined 45% sensitivity at 98% specificity.
Affiliation: Virginia G. Piper Center for Personal Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA. Department of Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, USA. Virginia G. Piper Center for Personal Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA. Electronic address: Karen.Anderson.1@asu.edu. .
Related Products: order online
5: Title: Blood Transcriptomic Markers in Patients with Late-Onset Major Depressive Disorder.
Authors: Miyata, Shigeo, et.al. .
Journal: PloS one, Vol. 11 (2): e0150262, 2016 .
Snippet: By assessing statistical significance using real-time quantitative PCR (RT-qPCR), the following 4 genes were selected as candidates: cell death-inducing DFFA-like effector c (CIDEC), ribonuclease 1 (RNASE1), solute carrier family 36 member-1 (SLC36A1), and serine/threonine/tyrosine interacting-like 1 (STYXL1).
Affiliation: Departments of Psychiatry and Neuroscience, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan. Department of Molecular and Cellular Neurobiology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan. Division of Neuropsychiatry, Department of Neuroscience, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan. .
Related Products: order online
6: Title: Proton Beams Inhibit Proliferation of Breast Cancer Cells by Altering DNA Methylation Status.
Authors: Kim, Byungtak, et.al. .
Journal: Journal of Cancer (Unknown Journal), Vol. 7 (3): 344-52, 2016 .
Snippet: Upon treatment with the proton beam, expression of selected genes (MDH2, STYXL1, CPE, FAM91A1, and GPR37) was significantly changed in accordance with the changes of methylation level.
Affiliation: 1. Department of Life Science, Dongguk University-Seoul, Goyang, Korea; 2. Korea Multi-purpose Accelerator Complex, Korea Atomic Energy Research Institute, Gyeongju, Korea. .
Related Products: order online
7: Title: Homozygous missense mutation in STYXL1 associated with moderate intellectual disability, epilepsy and behavioural complexities.
Authors: Isrie, Mala, et.al. .
Journal: European journal of medical genetics (Eur J Med Genet), Vol. 58 (4): 205-10, 2015 .
Snippet: A founder missense mutation was identified in STYXL1.
Affiliation: Center for Human Genetics, University Hospitals Leuven, KU Leuven, Leuven, Belgium; Laboratory for the Genetics of Cognition, KU Leuven, Leuven, Belgium. Center for Human Genetics, University Hospitals Leuven, KU Leuven, Leuven, Belgium. Department of Neurology, University Hospitals Leuven, KU Leuven, Leuven, Belgium. Center for Human Genetics, University Hospitals Leuven, KU Leuven, Leuven, Belgium; Laboratory for the Genetics of Cognition, KU Leuven, Leuven, Belgium. Electronic address: Hilde.VanEsch@uzleuven.be. .
Related Products: order online
8: Title: Low glucose transporter SLC2A5-inhibited human normal adjacent lung adenocarcinoma cytoplasmic pro-B cell development mechanism network.
Authors: You, Jingwen, et.al. .
Journal: Molecular and cellular biochemistry (Mol Cell Biochem), Vol. 399 (1-2): 71-6, 2015 .
Snippet: Based on GO, KEGG, GenMAPP, BioCarta, and disease databases, our result showed that low SLC2A5-inhibited network included Golgi apparatus of AP1M2_1; cell cycle of CUL7, SAC3D1; protein amino acid dephosphorylation of STYXL1; pro-B cell-cell differentiation of SOX4_3; and FAD biosynthesis of FLAD1.
Affiliation: Biomedical Center, School of Electronic Engineering, Beijing University of Posts and Telecommunications, Beijing, 100876, China. .
Related Products: order online
9: Title: MK-STYX, a catalytically inactive phosphatase regulating mitochondrially dependent apoptosis.
Authors: Niemi, Natalie M, et.al. .
Journal: Molecular and cellular biology (Mol Cell Biol), Vol. 31 (7): 1357-68, 2011 .
Snippet: We identified MK-STYX (STYXL1), a catalytically inactive phosphatase with homology to the mitogen-activated protein kinase (MAPK) phosphatases.
Affiliation: Laboratory of Systems Biology, Van Andel Research Institute, 333 Bostwick Ave. NE, Grand Rapids, MI 49503, USA. .
Related Products: order online
Documents per page: 20 | 50 | 100